Revision of EU GMP Chapter 1 to enhance Quality Risk Management

Recommendation
17/18 September 2025
Building a Knowledge Framework in GMP
According to the EMA's Work Plan for the GMP/GDP Inspectors Working Group for 2018, Chapter 1 of the EU-GMP Guidelines (Pharmaceutical Quality System) will be revised. The task is to "draft a proposal to amend the chapter in order to encourage industry adoption of risk-based approaches to prevention of shortages".
The document is also referring to the HMA/EMA Task force on availability of authorised medicines. If drug shortages are related to manufacturing or quality issues, will fall into the remit of EMA. The Agency has worked on how to best manage these shortages since 2012, resulting in the development of a comprehensive set of documents to support regulatory authorities in addressing shortage situations due to GMP non-compliance/quality defects. The task force is part of these activities.
One of these documents is the "Reflection paper on medicinal product supply shortages caused by manufacturing/Good Manufacturing Practice Compliance problems" (EMA/590745/2012). This reflection paper might give hints to what might be included in the revision of chapter 1. This paper for example refers to the increasing globalisation with extended manufacture and supply chains and its associated risks. It is mentioned that "industry's risk management tends to be very reactive rather than proactive" and that there is a need to bring "a change in a manufacturer's approach to quality risk management and supply chain security".
Source: EMA's Work plan for the GMP/GDP Inspectors Working Group for 2018
Related GMP News
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification
10.09.2025Why Human Error is not the End but the Beginning: Rethinking Deviation Management
03.09.2025Is QP Release possible after deviating In-Process Controls?